Cargando…
Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancers (NSCLCs) have favorable and impressive response to ALK tyrosine kinase inhibitors (TKIs). However, ALK rearrangement had approximately 90 distinct fusion partners. Patients with different ALK fusions might have distinct responses...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767047/ https://www.ncbi.nlm.nih.gov/pubmed/35070986 http://dx.doi.org/10.3389/fonc.2021.782682 |
_version_ | 1784634646120628224 |
---|---|
author | Zhai, Xiaoqian Wu, Qiang Pu, Dan Yin, Liyuan Wang, Weiya Zhu, Daxing Xu, Feng |
author_facet | Zhai, Xiaoqian Wu, Qiang Pu, Dan Yin, Liyuan Wang, Weiya Zhu, Daxing Xu, Feng |
author_sort | Zhai, Xiaoqian |
collection | PubMed |
description | Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancers (NSCLCs) have favorable and impressive response to ALK tyrosine kinase inhibitors (TKIs). However, ALK rearrangement had approximately 90 distinct fusion partners. Patients with different ALK fusions might have distinct responses to different-generation ALK-TKIs. In this case report, we identified a novel non-reciprocal ALK fusion: ALK-grancalcin (GCA) (A19: intragenic) and EML4-ALK (E20: A20) by next-generation sequencing (NGS) in a male lung adenocarcinoma patient who was staged as IIIB-N2 after surgery. After a multidisciplinary discussion, the patient received alectinib adjuvant targeted therapy and postoperative radiotherapy (PORT). He is currently in good condition, and disease-free survival (DFS) has been 20 months so far, which has been longer than the median survival time of IIIB NSCLC patients. Our study extended the spectrum of ALK fusion partners in ALK + NSCLC, and we reported a new ALK fusion: ALK-GCA and EML4-ALK and its sensitivity to alectinib firstly in lung cancer. It is vital for clinicians to detect fusion mutations of patients and report timely the newfound fusions and their response to guide treatment. |
format | Online Article Text |
id | pubmed-8767047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87670472022-01-20 Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy Zhai, Xiaoqian Wu, Qiang Pu, Dan Yin, Liyuan Wang, Weiya Zhu, Daxing Xu, Feng Front Oncol Oncology Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancers (NSCLCs) have favorable and impressive response to ALK tyrosine kinase inhibitors (TKIs). However, ALK rearrangement had approximately 90 distinct fusion partners. Patients with different ALK fusions might have distinct responses to different-generation ALK-TKIs. In this case report, we identified a novel non-reciprocal ALK fusion: ALK-grancalcin (GCA) (A19: intragenic) and EML4-ALK (E20: A20) by next-generation sequencing (NGS) in a male lung adenocarcinoma patient who was staged as IIIB-N2 after surgery. After a multidisciplinary discussion, the patient received alectinib adjuvant targeted therapy and postoperative radiotherapy (PORT). He is currently in good condition, and disease-free survival (DFS) has been 20 months so far, which has been longer than the median survival time of IIIB NSCLC patients. Our study extended the spectrum of ALK fusion partners in ALK + NSCLC, and we reported a new ALK fusion: ALK-GCA and EML4-ALK and its sensitivity to alectinib firstly in lung cancer. It is vital for clinicians to detect fusion mutations of patients and report timely the newfound fusions and their response to guide treatment. Frontiers Media S.A. 2022-01-05 /pmc/articles/PMC8767047/ /pubmed/35070986 http://dx.doi.org/10.3389/fonc.2021.782682 Text en Copyright © 2022 Zhai, Wu, Pu, Yin, Wang, Zhu and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhai, Xiaoqian Wu, Qiang Pu, Dan Yin, Liyuan Wang, Weiya Zhu, Daxing Xu, Feng Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy |
title | Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy |
title_full | Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy |
title_fullStr | Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy |
title_full_unstemmed | Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy |
title_short | Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy |
title_sort | case report: a novel non-reciprocal alk fusion: alk-gca and eml4-alk were identified in lung adenocarcinoma, which may respond to alectinib adjuvant-targeted therapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767047/ https://www.ncbi.nlm.nih.gov/pubmed/35070986 http://dx.doi.org/10.3389/fonc.2021.782682 |
work_keys_str_mv | AT zhaixiaoqian casereportanovelnonreciprocalalkfusionalkgcaandeml4alkwereidentifiedinlungadenocarcinomawhichmayrespondtoalectinibadjuvanttargetedtherapy AT wuqiang casereportanovelnonreciprocalalkfusionalkgcaandeml4alkwereidentifiedinlungadenocarcinomawhichmayrespondtoalectinibadjuvanttargetedtherapy AT pudan casereportanovelnonreciprocalalkfusionalkgcaandeml4alkwereidentifiedinlungadenocarcinomawhichmayrespondtoalectinibadjuvanttargetedtherapy AT yinliyuan casereportanovelnonreciprocalalkfusionalkgcaandeml4alkwereidentifiedinlungadenocarcinomawhichmayrespondtoalectinibadjuvanttargetedtherapy AT wangweiya casereportanovelnonreciprocalalkfusionalkgcaandeml4alkwereidentifiedinlungadenocarcinomawhichmayrespondtoalectinibadjuvanttargetedtherapy AT zhudaxing casereportanovelnonreciprocalalkfusionalkgcaandeml4alkwereidentifiedinlungadenocarcinomawhichmayrespondtoalectinibadjuvanttargetedtherapy AT xufeng casereportanovelnonreciprocalalkfusionalkgcaandeml4alkwereidentifiedinlungadenocarcinomawhichmayrespondtoalectinibadjuvanttargetedtherapy |